MedTrace Logo

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM

NCT02301806 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-02-17

No results posted yet for this study

Summary

To investigate whether single administration of sitaglitpin can restore acute endothelial dysfunction and ameliorate impaired increase of the number of endothelial progenitor cells (EPCs) after oral glucose loading in patients with T2DM.

To compare the effect of sitagliptin and glimepiride on endothelial function evaluated by flow-mediated vasodilatation (FMD) and the number of circulating EPCs in patients with T2DM.

Conditions

Interventions

OTHER

dieting

DRUG

Sitagliptin

sitagliptin 50 mg tablet by mouth 12 weeks

DRUG

Glimepiride

glimepiride 1 mg tablet by mouth 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Yoshimasa Aso · Dokkyo Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-06-30
Completion
2017-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02301806 on ClinicalTrials.gov